PREGABALIN AS A PREOPERATIVE ADJUVANT IN PATIENTS WITH CARPAL TUNNEL SYNDROME.

Acta Ortop Bras

Irmandade Santa Casa de Misericórdia de São Paulo, Departamento de Ortopedia e Traumatologia "Pavilhao Fernandinho Simonsen", Grupo de Mão e Microcirurgia, Sao Paulo, SP, Brazil.

Published: October 2024

Objective: To evaluate the pregabalins adjuvant effect in patients with carpal tunnel syndrome (CTS) surgically treated, analyzing postoperative pain and the incidence of complex regional pain syndrome (CRPS).

Methods: Outpatient surgical candidates with CTS were selected and followed for 12 months, divided into three groups. The Control Group received a placebo, the Pregabalin 75 mg Group received a daily dose, and the Pregabalin 150 mg Group received a daily dose of the medication. Patient progress was evaluated using the visual analog scale (VAS) for pain and the DN4 neuropathic pain score before surgery, one month and three months after.

Results: The administration of pregabalin to surgical patients with CTS did not demonstrate significant differences in immediate postoperative pain relief. Additionally, there were no statistically significant variations in the incidence of complications, such as CRPS, among the groups.

Conclusion: This study did not show a significant impact of pregabalin on postoperative pain relief or the reduction of CRPS incidence in patients undergoing surgery for CTS. These results suggest that pregabalin might not be an effective adjuvant in these surgical situations. .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530219PMC
http://dx.doi.org/10.1590/1413-785220243205e278892DOI Listing

Publication Analysis

Top Keywords

postoperative pain
12
group received
12
adjuvant patients
8
patients carpal
8
carpal tunnel
8
tunnel syndrome
8
received daily
8
daily dose
8
pain relief
8
pregabalin
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!